Clinical Trials Logo
  1. Home
  2. Dedifferentiated Liposarcoma
  3. NCT00969917

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma Clinical Trial

Official title:
A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Clinical Trial Summary

The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00969917
Study type Interventional
Source Infinity Pharmaceuticals, Inc.
Contact
Status Withdrawn
Phase Phase 2
Start date January 2010
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03307616 - Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Phase 2
Completed NCT01913652 - Ph II Cabazitaxel DD Liposarcoma Phase 2
Not yet recruiting NCT06389799 - A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Phase 2
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Active, not recruiting NCT06115681 - Real-world Study of Dedifferentiated Liposarcoma Patients in China
Active, not recruiting NCT02846987 - Study of Abemaciclib in Dedifferentiated Liposarcoma Phase 2
Terminated NCT04979442 - Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma Phase 3
Completed NCT02606461 - Selinexor in Advanced Liposarcoma Phase 2/Phase 3
Active, not recruiting NCT04242238 - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Phase 1
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Terminated NCT03604783 - Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05496569 - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma Phase 2